

Antifungal Drugs Market Expected to Grow from US\$ 11,135.3 Mn in 2021 to US\$ 13,997.4 Mn by 2028

Antifungal drugs market delivers a comprehensive study of the market, including its dynamics, structure, characteristics, Key player, growth & demand drivers.

NEW YORK, UNITED STATES, January 30, 2023 /EINPresswire.com/ -- The Insight Partners Latest Research for Report "[Antifungal Drugs Market](#) Forecast to 2028" Focuses Global Analysis by Infection Type (Superficial Fungal Infection and Systemic Fungal Infection), Drug Type (Echinocandins, Azoles, Polyenes, Allylamines and Others), Therapeutic Indication (Aspergillosis, Dermatophytosis, Candidiasis, and Others), and Dosage Form (Drugs, Ointment Powder and Others)

Latest study on "Antifungal Drugs Market Forecast to 2027 – Global Analysis – by Infection Type, Drug Type, Therapeutic Indication, and Dosage Form," the market is expected to grow from US\$ 11,135.3 million in 2021 to US\$ 13,997.4 million in 2028; it is expected to grow at a 3.3% from 2022 to 2028.

Download PDF Sample Copy at:

<https://www.theinsightpartners.com/sample/TIPRE00003745/>

The report highlights the key factors driving the market growth and prominent players with their developments in the market. The growth of the antifungal drugs market is primarily attributed to rising prevalence of fungal infections; increasing incidences of cancers, HIV, and hospital-acquired infections; and favorable government initiatives to combat the antifungal diseases. However, a lack of awareness regarding fungal infections is hampering the market growth.

Major highlights of the report:

- All-inclusive evaluation of the parent market
- Evolution of significant market aspects
- Industry-wide investigation of market segments
- Assessment of market value and volume in past, present, and forecast years
- Evaluation of market share
- Study of niche industrial sectors
- Tactical approaches of market leaders

- Lucrative strategies to help companies strengthen their position in the market

Segments:

Based on infection type, the antifungal drugs market is divided into superficial fungal infection and systemic antifungal infection. Based on drug type, the global antifungal drugs market is segmented into echinocandis, azoles, polyenes, allylamines, and others. In 2021, the azoles segment held the largest share of the market. However, the polyenes segment is expected to grow at the fastest rate during the forecast period. Azole antifungals are a group of medicines that contain an azole ring and prevent the growth of a wide range of fungi. Azole antifungal agents can be used to treat fungal infections of the body and skin, including athlete's foot, nail infections, ringworm, and vaginal candidiasis. Based on the dosage form, the market is segmented into drugs, ointment, powder, and others. Based on therapeutic indication, the market is segmented into aspergillosis, dermatophytosis, candidiasis, and others.

Have a Call with Analyst:

<https://www.theinsightpartners.com/speak-to-analyst/TIPRE00003745/>

Based on region, the global antifungal drugs market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The US is the largest market in North America. Asia Pacific is expected to exhibit the fastest growth due to growing healthcare infrastructure and evolving pharmaceutical & biopharmaceutical industries. Further, India is expected to grow at the highest CAGR in the Asia Pacific antifungal drugs market during the forecast period. The study conducted in 2015 by the Postgraduate Institute of Medical Education and Research (PGIMER) stated that 7 out of per 1,000 patient is affected with fungal infection. Also, the country has the presence of various pharmaceutical companies working on generic and innovative drug formulations. In addition, the pharmaceutical industry in the country is growing rapidly, which is expected to propel the market growth during the forecast period.

By geography, the global market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Key Companies are:

Pfizer Inc.

Sanofi S.A.

Gilead Sciences, Inc.

Merck And Co., Inc.

Scynexis Inc.

Novartis International AG

Abbott Laboratories
Bayer AG
Glenmark Pharmaceutical
Glaxosmithkline Plc.

Buy Report at:

https://www.theinsightpartners.com/buy/TIPRE00003745/?utm_source=EINPressWire&utm_medium=10376

About The Insight Partners:

The Insight Partners is a one top industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Manufacturing and Construction, Technology, Chemicals and Materials.

We offer our clients multiple ways to customize research as per their specific needs and budget.

Contact us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-987

Sameer Joshi

The Insight Partners

+ +91 96661 11581

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/614153923>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.